Corresponding Author: Maura Gillison, MD, PhD, Ohio State University, 420 W 12th Ave, Room 620, Columbus, OH 43210 (maura.gillison@osumc.edu).
Published Online: January 26, 2012. doi:10.1001/jama.2012.101
Author Contributions: Drs Gillison and Chaturvedi had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Gillison.
Acquisition of data: Gillison, Broutian, Pickard, Tong, Xiao.
Analysis and interpretation of data: Gillison, Broutian, Pickard, Tong, Xiao, Kahle, Graubard, Chaturvedi.
Drafting of the manuscript: Gillison, Broutian, Pickard, Tong, Xiao, Kahle, Chaturvedi.
Critical revision of the manuscript for important intellectual content: Gillison, Graubard, Chaturvedi.
Statistical analysis: Gillison, Pickard, Kahle, Graubard, Chaturvedi.
Obtaining funding: Gillison, Chaturvedi.
Administrative, technical or material support: Gillison, Broutian, Xiao.
Study supervision: Gillison.
Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Gillison is the principal investigator of the unrestricted grant from Merck in support of this study and has been a consultant to Merck and GlaxoSmithKline. No other disclosures were reported.
Funding/Support: This study was supported by the Ohio State University Comprehensive Cancer Center, Merck, John and Nina Cassils, and the Intramural Research Program of the National Cancer Institute.
Role of the Sponsors: Industry and philanthropic sponsors had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. Several authors are employees of Ohio State University or the National Cancer Institute.
Additional Contributions: We thank Brenda G. Lewis, MPH, National Center for Health Statistics (NCHS), and other staff members of NHANES/NCHS for their assistance in accomplishing the aims of the Oral HPV Protocol. None received compensation for the contributions besides salary from the federal vernment.
This article was corrected for errors on February 14, 2012.